ArchiveOctober 2011

The Big Knit comes home to Barts and The London

Barts and The London is very pleased to exhibit “Multiple Sclerosis: the big knit” from the 7- 11th November 2011. “Multiple Sclerosis: the big knit” is a collaborative science project where knitters from around the UK created three tableaux of MS. At the start of this year 150 knitters created over 300 objects to contribute to the woolly artwork. The project was created by the British Society...

ECTRIMS 2011: Barts and The London

If you are interested the following is a list of our contribution to ECTRIMS this year: Epstein-Barr virus and MS 8 G. Giovannoni (London, UK) Identification of Epstein-Barr Virus associated epigenetic changes and association with multiple sclerosis S. Ramagopalan, G. Ebers, U. Meier, G. Giovannoni (Oxford, London, UK) VSN16R a novel agent for the control of spasticity P 561 D. Baker, G. Pryce, C...

CCSVI: Pro-Data

Epub: Zivadinov R, Poloni GU, Marr K, Schirda CV, Magnano CR, Carl E, Bergsland N, Hojnacki D, Kennedy C, Beggs CB, Dwyer MG, Weinstock-Guttman B. Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency. BMC Neurol. 2011 ;11(1):128. “Good News for CCSVIers...

ECTRIMS: Alemtuzumab phase 3 results

Coles et al. Efficacy and safety results from CARE-MS I: a phase 3 study comparing alemtuzumab and interferon-beta-1a. Objective: Presentation of top line clinical efficacy and safety results from phase 3 pivotal study: Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis I (CARE-MS I) Background: Alemtuzumab is an anti-CD52 humanized monoclonal antibody that alters the circulating...

ECTRIMS: BG12 results

Gold et al. Clinical efficacy of BG-12, an oral therapy, in relapsing-remitting multiple sclerosis: data from the phase 3 DEFINE trial. Background: BG-12 (dimethyl fumarate) is an experimental oral treatment for relapsing-remitting multiple sclerosis (RRMS) that may have dual anti-inflammatory and neuroprotective effects via the Nrf2 pathway. In a Phase 2b trial, BG-12 reduced inflammatory...

ECTRIMS: Daclizumab results

Giovannoni et al. A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of daclizumab HYP monotherapy in relapsing-remitting multiple sclerosis: primary results of the SELECT trial.  Background: Daclizumab HYP (DAC HYP) is a humanized monoclonal antibody specific for the alpha subunit (CD25) of the human IL-2 receptor. DAC HYP modulates IL-2 signaling...

CCSVI at ECTRIMS

“Some food for thought; a selection of abstracts on CCSVI from the ECTRIMS/ACTRIMS/LACTRIMS meeting in Amsterdam.” P633: Haug et al. Intracranial venous pressure in MS is normal: ophthalmodynamometry data Conclusions: Our data give no evidence however of an increase in intracranial venous pressure. Venous congestion in MS patients is implausible. P631: Cavalla et al. CCSVI...

Epub ahead of print: Syc et al. Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain. 2011 Oct 17.  In post-mortem eyes there is loss of cells in the retina in MS’ers. Mini glossary: Post-mortem = after death Ganglion cells = specialised cells in the retina that integrate signals from the light sensing rods and cones...

B cell depletion in primate model of MS: is it ethical?

Epub ahead of print: Kap et al. B-Cell Depletion Attenuates White and Gray Matter Pathology in Marmoset Experimental Autoimmune Encephalomyelitis. J Neuropathol Exp Neurol. 2011 Oct 11. This study investigated the effect of B-cell* depletion on central nervous system white and gray matter pathology in experimental autoimmune encephalomyelitis (EAE) in common marmosets, a relevant...

Research News: Embryonic Stem Cells

It appears that a new European court ruling suggests that procedures that use embryonic stem cells cannot be patented. This has the knock-on effect that comapnies cannot directly profit from such discovery. However it should not mean that this is the end of stem cell research in Europe. According to “The Guardian” the decision from the European court results form a legal clarification...

Translate

Categories

Recent Posts

Recent Comments

Archives